Recently, at Hongene Biotech's high-tech GMP facility, Hongene Biotech and Syensqo officially signed a strategic cooperation framework agreement. This milestone event signifies that both parties will engage in deeper collaboration within the field of oligonucleotide therapeutics, jointly committed to providing innovative solutions for the global pharmaceutical market!
This collaboration will fully integrate Syensqo's extensive industry expertise in specialty phosphorus-containing chemicals with Hongene Biotech's robust capabilities in the development and production of oligonucleotide-based products. Both parties will jointly advance the R&D and market expansion of oligonucleotide therapeutics, aiming to achieve technological breakthroughs and market growth!
Through in-depth cooperation with Syensqo, Hongene Biotech will be able to achieve resource sharing and complementary advantages. Syensqo's technological strengths and influence in the field of specialty phosphorus-containing chemicals will assist us in further consolidating and expanding our market share and competitive edge in the oligonucleotide therapeutics market.
Both parties will jointly explore broader market spaces, continuously provide customers with more sustainable pharmaceutical solutions, drive development through innovation, and collectively contribute to the development of a Healthy world!
About Syensqo
Syensqo is a specialty chemicals company established following the separation of the former Solvay Group. We are science-based and dedicated to developing breakthrough solutions that improve the way we live, work, travel, and play. Inspired by the Solvay Conferences founded by Ernest Solvay in 1911, we bring together brilliant minds. Together with our more than 13,000 employees across 30 countries worldwide, we push the boundaries of science and innovation to benefit our customers. Our solutions enable safer, cleaner, and more sustainable products for homes, food and consumer goods, aircraft, automobiles, batteries, smart devices, and medical applications. We empower the ambition of a circular economy with our exceptional capacity for innovation, exploring technological breakthroughs and driving human progress.
About Hongene
Founded in 1998, Shanghai Hongene Biotech Development Co., Ltd. has over 20 years of extensive experience specializing in nucleic acid raw material production. Its product portfolio encompasses nucleosides and modified nucleosides, nucleotides, phosphoramidite monomers, GalNAc delivery molecules, and bioenzymes. The company possesses a phosphoramidite monomer product line with an annual capacity of 58 tons and an annual nucleotide triphosphate capacity of 54,000 liters, equivalent to the raw material demand for 10.5 billion doses of mRNA vaccines globally. The company has established long-term cooperative relationships with biotechnology and pharmaceutical companies worldwide, supplying materials for numerous clinical-stage and commercialized nucleic acid pipelines. Currently, the company has established service platforms for mRNA CDMO and Oligo CDMO. For more information about Hongene Biotech and its nucleic acid products, please visit Products page.